Breaking News

Actavis to Acquire Akorn Products

April 21, 2014

Expands portfolio of topical and ophthalmic generic products

Actavis plc has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. to acquire four marketed products and one product in development, for an undisclosed cash consideration. The closing of the agreements are contingent upon Akorn's acquisition of Hi-Tech. Last August, Akorn entered an agreement to acquire Hi-Tech for $640 million in cash.

The marketed products include Ciprofloxacin Hydrochloride Ophthalmic Solution, Levofloxacin Ophthalmic Solution, Lidocaine Hydrochloride Jelly, and Lidocaine/Prilocaine Topical Cream. 

"The acquisition of these products will complement our expanding portfolio of topical and ophthalmic generic products, and further strengthen our position as a leader in developing and marketing the complex, high-barrier products that provide enhanced value," said Siggi Olafsson, president, Actavis Pharma.

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus